Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant-Reference-Cited by-同舟云学术

Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant

Published:2017-03-21 Issue:5 Volume:15 Page:848-857
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Elalamy I.¹,Mahé I.²³,Ageno W.⁴,Meyer G.⁵⁶⁷

Affiliation:

1. Biological Hematology Department; Hôpital TENON APHP Hôpitaux Universitaires de l'Est Parisien; INSERM UMRS 938 Université Pierre et Marie Curie, Paris 6; Paris France

2. Internal Medicine Department; Hôpital Louis Mourier; APHP; Colombes France

3. Université Paris-Diderot Paris 7; EA 7334, Sorbonne Paris Cité; Paris France

4. Research Center on Thromboembolic Diseases and Antithrombotic Therapies; Department of Clinical and Experimental Medicine; University of Insubria; Varese Italy

5. Respiratory and Intensive Care; Hôpital Européen Georges Pompidou; APHP; Paris France

6. Université Paris Descartes Paris 5; Sorbonne Paris Cité; Paris France

7. INSERM UMRS 970; CIC 1418; Paris France

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13659/fullpdf

Reference70 articles.

1. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management;Donnellan;Curr Oncol,2014

2. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines;Mandala;Ann Oncol,2011